Small molecule Pharmaceuticals & Agrochemicals
Biopharmaceuticals
1973
Launched The Life Science Team to investigate the applicability of AGC’s fluorination technology to pharmaceutical & agrochemical production
1984
Formed the Biochemical Group focused on biopharmaceutical development
1985
Started contract manufacture/supply of fluorinated intermediates for use in antibiotics
1997
Developed Highly Efficient and Rapid Protein Production Technology "ASPEX" using fission yeast
1998
Established AGC Wakasa Fine Chemicals
(currently AGC Wakasa Chemicals)
(currently AGC Wakasa Chemicals)
2000
Formally launched the protein CMO business
2003
Established a GMP-compliant manufacturing facility for clinical stage drug substances and intermediates at Chiba Plant
2008
Obtained marketing approval for tafluprost, an anti-glaucoma drug substance developed jointly with Santen Pharmaceutical
2013
Established a new plant, Kaminaka Plant, in the Wakasa Techno-Valley (AGC Wakasa Chemicals)
2016
Acquired biopharmaceutical CDMO in Europe (currently Heidelberg site)
2017
Acquired biopharmaceutical CDMO with sites in U.S. and Europe (currently Seattle & Copenhagen sites)
2019
Acquired drug substance manufacturing plant in Spain (currently AGC Pharma Chemicals Europe)
2019
Increased GMP compliant production capacity 10-fold at Chiba Plant
2020
Acquired cell & gene therapy CDMO in Italia
(currently Milan site)
(currently Milan site)
2020
Acquired biopharmaceutical drug substance manufacturing plant in U.S. (currently Boulder site)
2021
Acquired gene therapy manufacturing plant in U.S. (currently Longmont site)
-
Developed Highly Efficient and Rapid Protein Production Technology "ASPEX" using fission yeast
-
Obtained marketing approval for tafluprost, an anti-glaucoma drug substance developed jointly with Santen Pharmaceutical
-
Established a new plant, Kaminaka Plant, in the Wakasa Techno-Valley (AGC Wakasa Chemicals)
-
Acquired biopharmaceutical CDMO with sites in Europe and U.S. (currently Seattle & Copenhagen sites)
-
Acquired drug substance manufacturing plant in Spain (currently AGC Pharma Chemicals Europe)
-
Acquired Italian cell & gene therapy CDMO (currently Milan site)
-
Acquired U.S. biopharmaceutical drug substance manufacturing plant (currently Boulder site)